Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria

Toxicon

Volumn 60, Issue 5, 2012, Pages 840-850

  Chang, Shih Chieh ^a   Galea, Charles A ^a   Leung, Eleanor W W ^a   Tajhya, Rajeev B ^b   Beeton, Christine ^b   Pennington, Michael W ^c   Norton, Raymond S ^a  

^a MONASH UNIVERSITY   (Australia)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Peptides International   (United States)

Author keywords

Isotopic labelling; NMR; Potassium channels; Protein expression; ShK

Indexed keywords

DIGLYCINE; ENTEROPEPTIDASE; HYBRID PROTEIN; NICKEL; POTASSIUM CHANNEL KV1.3; SEA ANEMONE TOXIN; SHK TOXIN; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; BACTERIAL CELL; DRUG EFFECT; ESCHERICHIA COLI; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; ISOTOPE LABELING; LYMPHOCYTE PROLIFERATION; NITROGEN NUCLEAR MAGNETIC RESONANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; T LYMPHOCYTE;

CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CNIDARIAN VENOMS; DNA PRIMERS; ESCHERICHIA COLI; ISOTOPE LABELING; MODELS, MOLECULAR; NITROGEN ISOTOPES; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PATCH-CLAMP TECHNIQUES; POLYMERASE CHAIN REACTION; POTASSIUM CHANNEL BLOCKERS; PROTEIN CONFORMATION; PROTEIN FOLDING; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; THIOREDOXINS;

ESCHERICHIA COLI; RATTUS;

EID: 84864035165     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2012.05.017     Document Type: Article

References (44)

1. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol. 2001, 166:936-944.
2. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13942-13947.
3. Beeton C., Chandy K.G. Induction and monitoring of adoptive delayed-type hypersensitivity in rats. J. Vis. Exp. 2007, e325.
4. Beeton C., Pennington M.W., Wulff H., Singh S., Nugent D., Crossley G., Khaytin I., Calabresi P.A., Chen C.Y., Gutman G.A., Chandy K.G. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol. Pharmacol. 2005, 67:1369-1381.
5. Beeton C.W., Pennington M.W., Norton R.S. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. Inflamm. Allergy Drug Targets 2011, 10:313-321.
6. Beeton C., Wulff H., Singh S., Botsko S., Crossley G., Gutman G.A., Cahalan M.D., Pennington M., Chandy K.G. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. J. Biol. Chem. 2003, 278:9928-9937.
7. Beeton C., Wulff H., Standifer N.E., Azam P., Mullen K.M., Pennington M.W., Kolski-Andreaco A., Wei E., Grino A., Counts D.R., Wang P.H., LeeHealey C.J., Andrews B.S., Sankaranarayanan A., Homerick D., Roeck W.W., Tehranzadeh J., Stanhope K.L., Zimin P., Havel P.J., Griffey S., Knaus H.-G., Nepom G.T., Gutman G.A., Calabresi P.A., Chandy K.G. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:17414-17419.
8. + channels, can be produced in Escherichia coli cytoplasm as a functional tagged protein. Protein Expr. Purif. 2004, 38:69-78.
9. Castaneda O., Sotolongo V., Amor A.M., Stocklin R., Anderson A.J., Harvey A.L., Engstrom A., Wernstedt C., Karlsson E. Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus. Toxicon 1995, 33:603-613.
10. Chi V., Pennington M.W., Norton R.S., Tarcha E.J., Londono L.M., Sims-Fahey B., Upadhyay S.K., Lakey J.T., Iadonato S., Wulff H., Beeton C., Chandy K.G. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon 2012, 59:529-546.
11. Chill J.H., Louis J.M., Miller C., Bax A. NMR study of the tetrameric KcsA potassium channel in detergent micelles. Protein Sci. 2006, 15:684-698.
12. + conduction and selectivity. Science 1998, 280:69-77.
13. Gallagher M.J., Blumenthal K.M. Cloning and expression of wild-type and mutant forms of the cardiotonic polypeptide anthopleurin B. J. Biol. Chem. 1992, 267:13958-13963.
14. + channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol. Pharmacol. 1994, 45:1227-1234.
15. Imai S., Osawa M., Takeuchi K., Shimada I. Structural basis underlying the dual gate properties of KcsA. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6216-6221.
16. Kalman K., Pennington M.W., Lanigan M.D., Nguyen A., Rauer H., Mahnir V., Paschetto K., Kem W.R., Grissmer S., Gutman G.A., Christian E.P., Cahalan M.D., Norton R.S., Chandy K.G. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide. J. Biol. Chem. 1998, 273:32697-32707.
17. Kawakami N., Nägerl U.V., Odoardi F., Bonhoeffer T., Wekerle H., Flügel A. Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion. J. Exp. Med. 2005, 201:1805-1814.
18. Kuang Z., Yao S., Keizer D.W., Wang C.C., Bach L.A., Forbes B.E., Wallace J.C., Norton R.S. Structure, dynamics and heparin binding of the C-terminal domain of insulin-like growth factor-binding protein-2 (IGFBP-2). J. Mol. Biol. 2006, 364:690-704.
19. Lange A., Giller K., Hornig S., Martin-Eauclaire M.F., Pongs O., Becker S., Baldus M. Toxin-induced conformational changes in a potassium channel revealed by solid-state NMR. Nature 2006, 440:959-962.
20. Lanigan M.D., Kalman K., Lefievre Y., Pennington M.W., Chandy K.G., Norton R.S. Mutating a critical lysine in ShK toxin alters its binding configuration in the pore-vestibule region of the voltage-gated potassium channel, Kv1.3. Biochemistry 2002, 41:11963-11971.
21. + channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:10094-10098.
22. Matheu M.P., Beeton C., Garcia A., Chi V., Rangaraju S., Safrina O., Monaghan K., Uemura M.I., Li D., Pal S., de la Maza L.M., Monuki E., Flugel A., Pennington M.W., Parker I., Chandy K.G., Cahalan M.D. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 2008, 29:602-614.
23. Moran Y., Cohen L., Kahn R., Karbat I., Gordon D., Gurevitz M. Expression and mutagenesis of the sea anemone toxin Av2 reveals key amino acid residues important for activity on voltage-gated sodium channels. Biochemistry 2006, 45:8864-8873.
24. + channels. Biochem. J. 2007, 406:41-48.
25. Pennington M.W., Beeton C., Galea C.A., Smith B.J., Chi V., Monaghan K.P., Garcia A., Rangaraju S., Giuffrida A., Plank D., Crossley G., Nugent D., Khaytin I., Lefievre Y., Peshenko I., Dixon C., Chauhan S., Orzel A., Inoue T., Hu X., Moore R.V., Norton R.S., Chandy K.G. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes. Mol. Pharmacol. 2009, 75:762-773.
26. Pennington M.W., Byrnes M.E., Zaydenberg I., Khaytin I., de Chastonay J., Krafte D.S., Hill R., Mahnir V.M., Volberg W.A., Gorczyca W., et al. Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone. Int. J. Pept. Protein Res. 1995, 46:354-358.
27. Pennington M.W., Lanigan M.D., Kalman K., Mahnir V.M., Rauer H., McVaugh C.T., Behm D., Donaldson D., Chandy K.G., Kem W.R., Norton R.S. Role of disulfide bonds in the structure and potassium channel blocking activity of ShK toxin. Biochemistry 1999, 38:14549-14558.
28. Pennington M.W., Mahnir V.M., Khaytin I., Zaydenberg I., Byrnes M.E., Kem W.R. An essential binding surface for ShK toxin interaction with rat brain potassium channels. Biochemistry 1996, 35:16407-16411.
29. Pennington M.W., Mahnir V.M., Krafte D.S., Zaydenberg I., Byrnes M.E., Khaytin I., Crowley K., Kem W.R. Identification of three separate binding sites on ShK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain. Biochem. Biophys. Res. Commun. 1996, 219:696-701.
30. Piotto M., Saudek V., Sklenar V. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J. Biomol. NMR 1992, 2:661-665.
31. Pohl J., Hubalek F., Byrnes M.E., Nielsen K.R., Woods A., Pennington M.W. Assignment of the three disulfide bonds in ShK toxin: a potent potassium channel inhibitor from the sea anemone Stichodactyla helianthus. Lett. Pept. Sci. 1995, 1:291-297.
32. Price M., Lee S.C., Deutsch C. Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:10171-10175.
33. Quintero-Hernández V., Ortiz E., Rendón-Anaya M., Schwartz E.F., Becerril B., Corzo G., Possani L.D. Scorpion and spider venom peptides: gene cloning and peptide expression. Toxicon 2011, 58:644-663.
34. + channels. J. Biol. Chem. 2000, 275:1201-1208.
35. Rauer H., Pennington M., Cahalan M., Chandy K.G. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin. J. Biol. Chem. 1999, 274:21885-21892.
36. Schanda P., Brutscher B. Very fast two-dimensional NMR spectroscopy for real-time investigation of dynamic events in proteins on the time scale of seconds. J. Am. Chem. Soc. 2005, 127:8014-8015.
37. Tudor J.E., Pallaghy P.K., Pennington M.W., Norton R.S. Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone. Nat. Struct. Biol. 1996, 3:317-320.
38. Tudor J.E., Pennington M.W., Norton R.S. Ionisation behaviour and solution properties of the potassium-channel blocker ShK toxin. Eur. J. Biochem. 1998, 251:133-141.
39. Turkov M., Rashi S., Noam Z., Gordon D., Ben Khalifa R., Stankiewicz M., Pelhate M., Gurevitz M. In vitro folding and functional analysis of an anti-insect selective scorpion depressant neurotoxin produced in Escherichia coli. Protein Expr. Purif. 1997, 10:123-131.
40. Wulff H., Beeton C., Chandy K.G. Potassium channels as therapeutic targets for autoimmune disorders. Curr. Opin. Drug Discov. Dev. 2003, 6:640-647.
41. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 2003, 111:1703-1713.
42. Yan L., Herrington J., Goldberg E., Dulski P.M., Bugianesi R.M., Slaughter R.S., Banerjee P., Brochu R.M., Priest B.T., Kaczorowski G.J., Rudy B., Garcia M.L. Stichodactyla helianthus peptide, a pharmacological tool for studying Kv3.2 channels. Mol. Pharmacol. 2005, 67:1513-1521.
43. Yao S., Headey S.J., Keizer D.W., Bach L.A., Norton R.S. C-terminal domain of insulin-like growth factor (IGF) binding protein 6: conformational exchange and its correlation with IGF-II binding. Biochemistry 2004, 43:11187-11195.
44. 15N heteronuclear correlation spectra acquired with band-selective pulses. J. Magn. Reson. 2011, 211:243-247.